Related Experiment Video
Updated: Mar 2, 2026
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Effect of ZEB2 silencing on cisplatin resistance in gastric cancer
1Department of Oncology, The Affiliated Yantai Yuhuagnding Hospital of Qingdao University, Yantai, Shandong, China. 18605452660@163.com.
Objective:
To investigate the effect of ZEB2 silencing on cisplatin resistance in gastric cancer.
Materials And Methods:
The resulting cell line, SGC7901/DDP, was transfected with ZEB2 siRNA, non-specific siRNA, or vehicle control. The effectiveness of ZEB2 silencing was evaluated by reverse transcriptase-polymerase chain reaction (RT-PCR) and Western blot. MTT viability assay was used to determine the cisplatin-sensitivity of cells. Cell apoptosis was measured by flow cytometry.
Results:
A significant decrease in ZEB2 in mRNA and protein level was seen in cells transfected with ZEB2 siRNA, compared to that in cells transfected with non-specific siRNA or vehicle. Transfection with ZEB2 siRNA in cisplatin-resistant SGC7901/DDP cells resulted in a significant decrease in cell viability in response to the cisplatin treatment, and cell viability decreased with increasing cisplatin concentrations. A higher apoptotic rate was also seen in cells transfected with ZEB2 siRNA under cisplatin treatment.
Conclusions:
ZEB2 silencing can effectively make gastric cells sensitive to cisplatin treatment in vitro.
Insights
Silencing ZEB2 (Zinc finger E-box binding homeobox 2) in gastric cancer cells significantly increased their sensitivity to cisplatin. This suggests ZEB2 as a potential therapeutic target for overcoming cisplatin resistance in gastric cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Gastric cancer remains a significant global health challenge.
- Cisplatin is a cornerstone chemotherapy agent, but resistance limits its efficacy.
- The role of ZEB2 in cisplatin resistance in gastric cancer requires further elucidation.
Purpose of the Study:
- To investigate the impact of ZEB2 gene silencing on cisplatin resistance in gastric cancer cells.
- To determine if reducing ZEB2 expression can re-sensitize resistant gastric cancer cells to cisplatin.
Main Methods:
- Gastric cancer cell line SGC7901/DDP (cisplatin-resistant) was utilized.
- Cells were transfected with ZEB2 siRNA to achieve gene silencing.
- Reverse transcriptase-polymerase chain reaction (RT-PCR) and Western blot confirmed ZEB2 knockdown.
- MTT assay assessed cell viability and cisplatin sensitivity.
- Flow cytometry measured apoptosis rates.
Main Results:
- ZEB2 siRNA transfection effectively reduced ZEB2 mRNA and protein levels.
- Silencing ZEB2 significantly decreased cell viability in cisplatin-treated SGC7901/DDP cells.
- A dose-dependent decrease in cell viability was observed with increasing cisplatin concentrations post-ZEB2 silencing.
- ZEB2 silencing led to a higher apoptotic rate in cells exposed to cisplatin.
Conclusions:
- ZEB2 silencing effectively restores sensitivity to cisplatin in gastric cancer cells in vitro.
- Targeting ZEB2 presents a promising strategy to overcome cisplatin resistance in gastric cancer.
